PharmTech Drug Digest 11.20
Publication|Articles|August 21, 2024

Pharmaceutical Technology Editorial Advisory Board

Listen
0:00 / 0:00

Key Takeaways

  • The double-blind peer-review process ensures unbiased evaluation of technical articles by the Editorial Advisory Board (EAB).
  • EAB members are experts from various pharmaceutical industry sectors, contributing to content quality and relevance.
SHOW MORE

Pharmaceutical Technology North America and Pharmaceutical Technology Europe magazines publish contributed technical articles that undergo a double-blind peer-review process involving members of our distinguished Editorial Advisory Boards (EAB). The EAB are specialists representing various facets of the pharmaceutical industry. EAB members review manuscripts, recommend subject matter and answer questions when they arise.

  • Larry L. Augsburger, PhD, Professor Emeritus, University of Maryland School of Pharmacy
  • Reinhard Baumfalk, Vice President Global Engineering Factory Automation, Emerson Automation Solutions
  • Phil Borman, DSc, CChem, FRSC, Senior Director QbD & Digital Platform Portfolio & Technology Delivery, Medicine Development & Supply, Pharma R&D, GSK
  • Evonne Brennan, Consultant at Evonne Brennan Consulting
  • Rory Budihandojo, Independent GMP Consultant
  • Christopher Burgess, Managing Director, Burgess Analytical Consultancy
  • Metin Çelik, PhD, President, Pharmaceutical Technologies International (PTI)
  • Robert Dream, Managing Director, HDR Company
  • Manish Garg, PMP, PSM, Associate Director, IT Application, Serialization, Track & Trace, Hikma
  • Sanjay Garg, PhD, Professor and Director, Centre for Pharmaceutical
    Innovation and Development, University of South Australia
  • Filipe Gaspar, Vice-President Technology Intensification
    Hovione
  • Ruey-ching (Richard) Hwang, PhD, Executive Director, Clinical Supply Operations, Pfizer Global R&D
  • Henrik Johanning, CEO, Senior Consultant, Genau & More A/S
  • Mansoor A. Khan, PhD, Regents Professor and Vice Dean, Presidential Impact Fellow, Rangel College of Pharmacy, Texas A&M University
  • Heidi M. Mansour, PhD, Professor, Center for Translational Science, FIU Center for Translational Science
  • R. Christian Moreton, PhD, Partner, FinnBrit Consulting
  • Fernando J. Muzzio, PhD, Distinguished Professor, Chemical and Biochemical, Engineering Rutgers University
  • Christa Myers, Senior Fellow–Aseptic & Sterile Products, CRB
  • Moheb M. Nasr, PhD, Principal, Nasr Pharma Regulatory Consulting
  • Siegfried Schmitt, PhD, Vice‑President Technical, PAREXEL International
  • Susan. J. Schniepp, Distinguished Fellow, Regulatory Compliance Associates. Click HERE for a spotlight on Sue Schniepp.
  • David R. Schoneker, President, Black Diamond Regulatory Consulting
  • Aloka Srinivasan, Principal and Managing Partner, RAAHA LLC
  • Griet Van Vaerenbergh, Marketing Manager Pharma Solid Dosage, GEA Process Engineering

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.